Abstract 5172
Background
The aim of the present study was to investigate predictors of survival in a cohort of patients with incurable cancer. This may highlight areas of care which can be addressed to optimise outcomes.
Methods
Patient demographics, performance status (ECOG), inflammatory markers (modified Glasgow Performance Score (mGPS)), and nutritional parameters [BMI, % weight loss (WL)] were recorded. Baseline body composition were examined using computed tomography (CT) images. Sarcopenia and low muscle attenuation (MA) were defined using published cut-offs. Cancer cachexia (CC) was defined using the consensus definition (2011). Cox models were used to estimate mortality hazard ratios, adjusted for known prognostic covariates – age, sex & site.
Results
In total, 1027 patients were recruited (51% male, median age 66 years). Gastrointestinal cancer was most common (40%) and metastatic disease was present in 87% of patients. In total, 86% were on active chemotherapy treatment. On multivariate analysis, primary site, ECOG-PS, WL and mGPS predicted survival. Lung and GI cancer patients had higher risk of death compared to other tumour groups [HR:1.769 (95% CI:1.305–2.398), p < 0.001 and HR:1.576 (95% CI:1.211–2.053), p = 0.001, respectively]. mGPS score of 1 or 2 were associated with increased risk of death versus mGPS of 0 [HR:1.399 (95% CI:1.024–1.910), p = 0.035 & HR:1.831 (95% CI:1.442–2.324), p < 0.001, respectively]. WL > 10% in the preceding 3 months was associated with reduced survival [HR:2.501 (95% CI:1.425–4.389), p = 0.001]. Sarcopenia, CC and low MA were significant predictors of survival on univariate analysis, but not on multivariate analysis.
Conclusions
Independent predictors of survival in this cohort of advanced cancer patients were cancer site, ECOG, WL > 10% and mGPS, the latter two being important components of the cancer cachexia syndrome. Attenuation of weight loss and inflammation may improve outcomes for patients undergoing palliative treatment for cancer.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2728 - MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma
Presenter: Melissa Vos
Session: Poster Display session 1
Resources:
Abstract
3197 - Genomic Alterations, Tumor Mutation Burden and Prognosis of Chinese Cardiac Sarcoma Patients
Presenter: Na Zhu
Session: Poster Display session 1
Resources:
Abstract
4214 - Evaluation of a peptide-conjugated alkylator melflufen in osteosarcoma preclinical models
Presenter: Konstantin Byrgazov
Session: Poster Display session 1
Resources:
Abstract
2654 - Expression analysis of NHEJ and HR genes in Ewing sarcomas: indications of DSB repair dysfunction
Presenter: Anastasios Kyriazoglou
Session: Poster Display session 1
Resources:
Abstract
4383 - Epidemiology of Synovial Sarcoma in EU28 countries
Presenter: Nedra Joseph
Session: Poster Display session 1
Resources:
Abstract
1937 - Resection Of High-Grade Large Soft Tissue Sarcoma With Adequate Wide Margin Can Lead To Good Local Control Without Adjuvant Radiotherapy
Presenter: Toshiyuki Kunisada
Session: Poster Display session 1
Resources:
Abstract
3757 - Influence of eribulin on proliferation, migration and invasion properties of leiomyosarcoma cell line models
Presenter: Marta Mendiola
Session: Poster Display session 1
Resources:
Abstract
1040 - EREMISS: Efficacy of regorafenib (REG) as maintenance therapy in non-adipocytic soft tissue sarcomas (STS) having received 1st-line doxorubicin-based chemotherapy (Doxo-CT)
Presenter: Nicolas Penel
Session: Poster Display session 1
Resources:
Abstract
1048 - A Phase 2 biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, a disease with a high unmet need
Presenter: Kan Yonemori
Session: Poster Display session 1
Resources:
Abstract
1511 - A pilot study of oral paclitaxel (ORAXOL) in subjects with cutaneous angiosarcomas (KX-ORAX-010)
Presenter: Herbert Loong
Session: Poster Display session 1
Resources:
Abstract